A Phase 2 interventional study of Febuxostat and Placebo in Hypertension, sponsored by Takeda. Completed at 46 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-31.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Hypertension · Takeda.
Among the 44 studies in Hypertension by Takeda, this one is the 23rd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2012, is one of 4 in phase 2, and was the 26th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 44 studies in Hypertension by Takeda is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 26 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 383 across the 34 interventional studies, 2,647 across the 10 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hypertension by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).
This study is designed to evaluate the effect of febuxostat during 6 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is male and at least 18 years of age, or a female who is:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
Drug: Febuxostat
Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Drug: Placebo
Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
Also known as: TMX-67, Uloric
Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6
The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6
The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6
Change From Baseline in Serum Urate Levels at Week 6
Time frame: Baseline and Week 6
Participants took part at 29 sites in the United States from 10 January 2012 to 04 August 2014.
| Milestone | Placebo | Febuxostat 80 mg |
|---|---|---|
| Started | 60 | 61 |
| Completed | 50 | 53 |
| Not completed | 10 | 8 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Bp exceeds protocol limits | 1 | 2 |
| Withdrew: Other | 1 | 1 |
The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| millimeters of mercury (mmHg) | Placebo | Febuxostat 80 mg |
|---|---|---|
| Baseline | 142.3 ± 1.21 | 139.5 ± 1.18 |
| Change at Week 6 | -3.4 ± 1.31 | -3.7 ± 1.27 |
The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Placebo | Febuxostat 80 mg |
|---|---|---|
| Baseline | 85.9 ± 1.14 | 83.0 ± 1.11 |
| Change at Week 6 | -2.7 ± 0.91 | -2.0 ± 0.88 |
| mg/dL | Placebo | Febuxostat 80 mg |
|---|---|---|
| Baseline | 7.7 ± 0.14 | 7.6 ± 0.14 |
| Change at Week 6 | 0.1 ± 0.17 | -3.3 ± 0.17 |
Collected over Treatment-emergent AEs are defined as any AEs, regardless of relationship to study drug, which occurs on or after the first double-blind dose date and up to 30 days after the last dose date of the double-blind study drug.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/60 (1.7%) | 1/60 (1.7%) |
| Febuxostat 80 mg | — | 1/61 (1.6%) | 3/61 (4.9%) |
| Event | Placebo | Febuxostat 80 mg |
|---|---|---|
| Blood pressure increasedInvestigations | 1/60 | 0/61 |
| Coronary artery insufficiencyCardiac disorders | 0/60 | 1/61 |
| Event | Placebo | Febuxostat 80 mg |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/60 | 3/61 |
The Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.
| Age, Continuous(years) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Mean | 55.08 ± 10.607 | 52.15 ± 10.469 | 53.60 ± 10.597 |
| Age, Customized(participants) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Less than (<) 45 years | 8 | 14 | 22 |
| 45 - <65 years | 44 | 43 | 87 |
| Greater than or equal to (>=) 65 years | 8 | 4 | 12 |
| Sex: Female, Male(Participants) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Female | 12 | 11 | 23 |
| Male | 48 | 50 | 98 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 7 | 8 | 15 |
| Black or African American | 11 | 10 | 21 |
| White | 42 | 41 | 83 |
| More than one race | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 14 | 23 |
| Not Hispanic or Latino | 51 | 47 | 98 |
| Region of Enrollment(participants) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| United States | 60 | 61 | 121 |
| Height(centimeter (cm)) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Mean | 172.10 ± 8.564 | 173.33 ± 9.206 | 172.72 ± 8.878 |
| Weight(kilogram (kg)) | Placebo | Febuxostat 80 mg | Total |
|---|---|---|---|
| Mean | 95.35 ± 21.199 | 100.88 ± 19.490 | 98.14 ± 20.460 |
7 further baseline measures are reported on the registry.
The record gives a start of Feb 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat